DR. BRIAN SCHREIBER, MD
Osteopathic Medicine at Forest Manor Ct, Neenah, WI
License number
Wisconsin 34190
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Wisconsin 34190
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
2414 Forest Manor Ct, Neenah, WI 54956
Phone
(920) 886-1804
Organization information
See more information about BRIAN SCHREIBER at bizstanding.comBrian Schreiber
Neenah, WI - Appleton, WI
Industry:
Medical Doctor's Office
Doing business as:
Fox Valley Nephrology
Addresses:
300 N Commercial St, Neenah, WI 54956
PO Box 2787, Appleton, WI 54912
PO Box 2787, Appleton, WI 54912
Nurse Practitioners:
Osaid Ahmad (Nephrology),Kim R. Riess-Sagers (Medical Doctor, Nephrology, Partner),Atif A. Qureshi (Medical Doctor, Nephrology),...
Professional information
Brian Schreiber - Neenah, WI
Work:
Medical Affairs, Sigma Tau Pharmaceuticals
Vice President Sigma Tau Pharmaceuticals
Consultant St. Elizabeth Hospital and Appleton Medical Center
Associate Staff, Nephrology St. Elizabeth Hospital and Appleton Medical Center Sigma Tau Pharmaceuticals
Member, Board of Directors Wisconsin Society Sigma Tau Pharmaceuticals
Consultant Medical Director Sigma Tau Pharmaceuticals
Chief Medical Director National Kidney Foundation of Wisconsin
Member Board Certified Nephrology FMC - Appleton, WI
Medical Director FMC - Appleton, WI
President FMC - Appleton, WI
Chairman National Kidney Foundation of Wisconsin
Member, Board of Directors Cornell University Health Services - Ithaca, NY
Attending Physician Department of Internal Medicine
Associate Staff Board Certified Internal Medicine
Vice President Sigma Tau Pharmaceuticals
Consultant St. Elizabeth Hospital and Appleton Medical Center
Associate Staff, Nephrology St. Elizabeth Hospital and Appleton Medical Center Sigma Tau Pharmaceuticals
Member, Board of Directors Wisconsin Society Sigma Tau Pharmaceuticals
Consultant Medical Director Sigma Tau Pharmaceuticals
Chief Medical Director National Kidney Foundation of Wisconsin
Member Board Certified Nephrology FMC - Appleton, WI
Medical Director FMC - Appleton, WI
President FMC - Appleton, WI
Chairman National Kidney Foundation of Wisconsin
Member, Board of Directors Cornell University Health Services - Ithaca, NY
Attending Physician Department of Internal Medicine
Associate Staff Board Certified Internal Medicine
Education:
Medical College of Wisconsin - Milwaukee, WI
Clinical Professor of Medicine University of Vermont School of Medicine
Nephrology Center Hospital of Vermont - Burlington, VT
Nephrology, Medical State University of New York, School of Medicine at Buffalo - Buffalo, NY
M.D. Brandeis University - Waltham, MA
Bachelor of Arts
Clinical Professor of Medicine University of Vermont School of Medicine
Nephrology Center Hospital of Vermont - Burlington, VT
Nephrology, Medical State University of New York, School of Medicine at Buffalo - Buffalo, NY
M.D. Brandeis University - Waltham, MA
Bachelor of Arts
Dr. Brian D Schreiber - MD (Doctor of Medicine)
Hospitals:
1519 Paynes Point Rd, Neenah 54956
1519 Paynes Point Rd, Neenah 54956
1519 Paynes Point Rd, Neenah 54956
Education:
Medical Schools
State University of New York At Buffalo
Graduated: 1980
State University of New York At Buffalo
Graduated: 1980
Methods For The Diagnosis Of Hemodialysis Patients And Utilization Of Such Methods To Improve The Administration Of Intravenous Levocarnitine Treatments To Hemodialysis Patients
US Patent:
7333894, Feb 19, 2008
Filed:
Jan 31, 2003
Appl. No.:
10/355263
Inventors:
Brian Schreiber - Neenah WI, US
Vyonne T. Lewis - New Orleans LA, US
Vyonne T. Lewis - New Orleans LA, US
Assignee:
Sigma-Tau Pharmaceuticals, Inc. - Gaithersburg MD
International Classification:
G01N 33/48
US Classification:
702 19, 702 20, 703 11, 707102
Abstract:
The disclosed invention pertains to methods for diagnosing clinical conditions that are common in hemodialysis patients and that may be related to abnormal carnitine metabolism resulting from hemodialysis. Further, the present invention pertains to methods for monitoring and improving the administration of therapeutic intravenous levocarnitine to such patients. Clinical algorithms have been developed for the clinical symptoms seen in end-stage renal disease (ESRD) patients that may be related to carnitine deficiency. Monitoring tools to assist healthcare professionals in implementing the clinical algorithms are also provided.
Prevention And Treatment Of Metabolic Abnormalities Associated With Excess Intramyocellular Lipid
US Patent:
2005023, Oct 20, 2005
Filed:
Apr 19, 2005
Appl. No.:
11/109148
Inventors:
Brian Schreiber - Neenah WI, US
International Classification:
A61K038/43, A61K031/555, A61K031/426, A61K031/202, A61K031/155, A61K031/17, A61K031/385
US Classification:
424094100, 514184000, 514369000, 514440000, 514595000, 514635000, 514560000
Abstract:
Compositions and methods for treating and/or preventing metabolic syndrome in a subject exhibiting clinical and/or biochemical manifestations of metabolic syndrome, or being predisposed to developing metabolic syndrome, or a precursor indicator for metabolic syndrome. The method comprises administering a pharmaceutically-effective form of carnitine or a pharmaceutically acceptable salt thereof, alone or in combination with another agent, optionally in sustained-release format, in an amount effective to treat at least one symptom of metabolic syndrome or a precursor indicator for metabolic syndrome.